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Introduction
Colorectal cancer is the third most frequent type of cancer in 
Germany with expected 61,000 newly diagnosed cases in 2016 [1]. 
The median age at diagnosis is about 70 years. Approximately 25% 
of the patients show synchronous metastases and 25% develop me-
tastases during the course of the disease [2]. Metastatic colorectal 
cancer (mCRC) has a critical prognosis with a 5-year survival rate 
of less than 10% [3]. In Germany, mCRC leads to 26,000 deaths per 
year [1]. Treatment of mCRC has undergone substantial changes 
in the last 20 years. New therapeutics and combination regimens 
have led to marked improvements in both response rate (RR) and 
overall survival (OS). This article provides an overview of the cur-
rent standard of care and future perspectives in the systemic treat-
ment of mCRC.
Choice of First-Line Treatment
General Aspects
In general, the choice of first-line treatment should be influ-
enced by the tolerability of the medication as well as the patient’s 
comorbidities, biological age, and preferences. It is important to 
emphasize that decisions regarding the first-line treatment are cru-
cial for the patient’s outcome: first-line treatment has a signifi-
cantly higher overall response rate (ORR) and longer progression-
free survival (PFS) than consecutive treatment lines [4]. Further-
more, the fraction of patients receiving chemotherapy decreases 
with each treatment line [5]. Finally, the choice of first-line treat-
ment defines the possible consecutive regimens.
Therapeutics and Regimens
Standard of care for the majority of patients is the combination 
of 5-fluorouracil (FU)/leucovorin (LV) with either oxaliplatin 
(FOLFOX) or irinotecan (FOLFIRI) together with a monoclonal 
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Summary
Palliative chemotherapy for metastatic colorectal cancer 
has undergone substantial changes in recent years. The 
implementation of modern biologicals in the treatment 
has substantially improved overall survival up to 30 
months. With the increasing number of therapeutic op-
tions, the question of optimal treatment sequence arises, 
which is addressed in current studies like FIRE 4 or 
STRATEGIC-1. Furthermore, clinical and molecular bio-
markers to predict efficacy and tolerability are urgently 
needed. Today, the detection of activating RAS muta-
tions is the only validated biomarker which precludes 
patients from anti-EGFR treatment. The detection of 
BRAF mutation V600E is associated with a very poor 
prognosis corresponding to a survival of 9–12 months. 
Prospective trials evaluating an optimal approach to this 
subgroup are still missing. First results from strategies 
targeting the aberrant signal transduction are promising 
and require further validation. Despite the advances so 
far, life expectancy unfortunately continues to be limited 
in the majority of patients with metastatic colorectal can-
cer. New strategies are needed to improve the progno-
sis. To this end, the identification of Her2/neu as a poten-
tial target and first experiences with checkpoint inhibi-
tion in patients with mismatch repair-deficient tumors 
are promising and also require further validation.
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antibody (moAb) against either vascular endothelial growth factor 
(VEGF) or epidermal growth factor receptor (EGFR) [6]. Bevaci-
zumab is a moAb against VEGF, whereas cetuximab and panitu-
mumab are directed against EGFR. All three are approved for first-
line treatment in mCRC.
FOLFOX and FOLFIRI show a comparable efficacy regarding 
OS [7]. For clinically fit patients, a higher ORR and a longer OS 
can be achieved with the triple combination of FOLFOXIRI alone 
[8] or in combination with bevacizumab [9]. Intravenous 5-FU can 
be replaced by the oral fluoropyrimidine capecitabine either in 
combination with oxaliplatin (CapOx) [10] or irinotecan (CapIri) 
[11]. In general, capecitabine should not be combined with cetuxi-
mab due to negative results obtained in the COIN study [12]. Espe-
cially for elderly patients, the combination of capecitabine and 
bevacizumab is effective and well tolerated [13].
Cetuximab and panitumumab are both approved for first-line 
treatment with either FOLFIRI or FOLFOX [14–16]. The approval 
of bevacizumab in the first-line setting is based on a phase III trial 
Table 1. Summary of important clinical trials in the authors’ view (according to [4])








Falcone et al. [8] III FOLFIRI 122 34  6.9
0.63
16.7
0.70FOLFOXIRI 122 60  9.8 22.6
Tournigand et al. [7] III FOLFIRI 109 56  8.5
–
21.5
–FOLFOX 111 54  8.1 20.6
CRYSTALa [14] III FOLFIRI 350 39.7  8.4
0.696
20.0
0.796cFOLFIRI + cetuximab 316 57.3  9.9 23.5
OPUSa [15] II FOLFOX  97 34.0  7.2
0.567
18.5
0.855cFOLFOX + cetuximab  82 57.3  8.3 22.8
PRIMEb [16] III FOLFOX 253 –  7.9
0.72
20.2
0.77FOLFOX + panitumumab 259 – 10.1 25.28
NO16966 [10] III FOLFOX/XELOX 701 38.0  8.0
0.83
21.3
0.89cFOLFOX/XELOX + bevacizumab 699 38.0  9.4 19.9
Hurwitz et al. [17] III IFL + placebo 411 34.8  6.2
0.62
15.6
0.66IFL + bevacizumab 402 44.8 10.6 20.3
FIRE-3b [45, 46] III FOLFIRI + cetuximab 171 66 10.4
0.97c
33.1
0.697FOLFIRI + bevacizumab 171 60 10.2 25.6
CALGB-80405b* [47] III chemotherapy + cetuximab 270 68.6 11.4
1.1c
32.0
0.9cchemotherapy + bevacizumab 256 53.8 11.3 31.2
PEAKb [48] II FOLFOX + panitumumab  88 63 13.0
0.65
41.3
0.63cFOLFOX + bevacizumab  82 60  9.5 28.9
TRIBE [9] III FOLFIRI + bevacizumab 256 54  9.7
0.77
25.8
0.80FOLFOXIRI + bevacizumab 252 65 12.3 29.8
AVEX [13] III capecitabine 140 10  5.1
0.53
16.8
0.79ccapecitabine + bevacizumab 140 19  9.1 20.7
Second and further line studies
E3200 [30] III FOLFOX 291  8.6  4.7
0.61
10.8
0.75FOLFOX + bevacizumab 286 22.7  7.3 12.9
TML [31] III chemotherapy 411  4  4.1
0.68
 9.8
0.81chemotherapy + bevacizumab 409  5  5.7 11.2
VELOUR [32] III FOLFIRI 614 11.1  4.7
0.76
12.1
0.82FOLFIRI + aflibercept 612 19.8  6.9 13.5
RAISE [33] III FOLFIRI + placebo 536 72  4.5
0.793
11.7
0.844FOLFIRI + ramucirumab 536 67  5.7 13.3
CORRECT [35] III placebo + BSC 255  0.4  1.7
0.49
 6.4




*Only data from 526 patients available. 
Presented hazard ratios are all significant if not otherwise indicated.
Primary study end points are presented in italics.
BSC = Best supportive care; ORR = overall response rate; PFS = progression-free survival; HR = hazard ratio; OS = overall survival.
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using an irinotecan-containing combination (IFL), which is no 
longer common due to toxicity [17, 18]. A study evaluating bevaci-
zumab first-line in combination with oxaliplatin-based regimens 
could only demonstrate a benefit regarding PFS, while it was minor 
and non-significant concerning OS [10]. The optimal sequence of 
anti-EGFR and anti-VEGF strategy in patients without correspond-
ing contraindications is still under debate and warrants further in-
vestigation. Key studies of this review are summarized in table 1.
Predictive and Prognostic Factors
So far, the only established predictive biomarker in the treatment 
of mCRC is the detection of activating mutations in KRAS (Kirsten 
RAS) or NRAS (neuroblastoma RAS) oncogene. These mutations 
occur in about 50% of mCRC and affect exons 2–4 in both genes 
[16]. Activated RAS can bypass the antiproliferative effects of anti-
EGFR antibodies and patients with RAS mutation do not profit from 
such treatment [16, 19]. In combination with oxaliplatin, anti-EGFR 
treatment could even harm these patients [16]. Hence, testing the 
patient’s tumor samples for RAS mutation is obligatory [6]. Cetuxi-
mab and panitumumab are contraindicated if a RAS mutation is de-
tected. This also includes KRAS p.G13D mutation since more recent 
evidence indicates that also this subgroup does not benefit from the 
addition of cetuximab to chemotherapy [20, 21].
Besides testing for RAS mutation, the expected ESMO Clinical 
Practice Guidelines (initial presentation at the ECC conference 
2015) will also advise to test for BRAF mutation V600E in patients 
with mCRC. This mutation can be found in 8–10% of patients and 
is associated with a poor prognosis [16, 22].
Treatment of Patients with RAS-Mutated Tumors
Patients with RAS-mutated tumor have fewer treatment options 
because anti-EGFR strategies are contraindicated. While optimal 
treatment of this subgroup is unclear, chemotherapy is mostly 
combined with bevacizumab in the first-line setting. Taking into 
account the results of the TML trial, the continuation of treatment 
with bevacizumab beyond first progression leads to a moderate but 
statistically significant prolongation of OS irrespective of KRAS 
mutation status [23].
Treatment of Patients with RAS Wild-Type Tumors
For patients without RAS mutation all approved first-line options 
are available. Whether optimal first-line treatment should contain 
an anti-EGFR or an anti-VEGF agent has recently been the focus of 
a controversial debate. Altogether, three trials address this question: 
FIRE-3, CALGB-80405, and PEAK (for details see table 1). A meta-
analysis taking the three trials into account shows superior ORR and 
OS with first-line anti-EGFR therapy compared with anti-VEGF 
therapy. According to these results, it seems reasonable to initiate 
treatment of RAS wild-type patients with an anti-EGFR strategy [4], 
especially if tumor shrinkage is the primary aim [24].
Treatment of Patients with BRAF Mutation
The prognosis of patients with BRAF mutation is very poor 
with a median OS of 9–14 months [9, 15, 22]. In this subgroup, the 
TRIBE study comparing bevacizumab plus either FOLFIRI or 
FOLFOXIRI revealed a profound benefit for the more intensive 
regimen and should be considered in these patients [9].
Treatment of Patients with Resectable Metastases
For patients with primarily resectable liver or lung metastases, 
upfront resection is an option, especially if metastases are limited 
in number and size [6]. In the EPOC study, perioperative chemo-
therapy with FOLFOX has increased PFS (primary end point) 
without significant impact on OS [25]. The approach to these pa-
tients should ideally be defined in a multidisciplinary team taking 
the individual patient’s context into account [4]. After complete 
resection of colorectal metastases, some evidence suggests an addi-
tive 5-FU-based chemotherapy [26]. According to the results of the 
recent New EPOC study, patients with resectable liver metastases 
should not be treated with cetuximab plus chemotherapy [27].
Figure 1 indicates a possible approach to choose first-line treat-
ment for patients with mCRC.
BRAF RAS RAS RAS RAS 
Fig. 1. Possible  
approach to choose 
first-line treatment for 
patients with mCRC 
(adapted according to 
the ESMO Pocket 
Guidelines 2015 Lower 
Gastrointestinal  
Cancer, Section  
metastatic colorectal 
cancer). FP = Fluoro-
pyrimidin; CT = chem-
otherapy.
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Strategy after Initial Treatment
Maintenance Therapy
Especially in the context of oxaliplatin-containing regimens, the 
duration is frequently limited due to cumulative neurotoxicity. 
Hence, several studies have examined a strategy with de-escalation 
after an initial treatment phase followed by a maintenance therapy 
with re-escalation in the case of progressive disease. For 5-FU/LV/
oxaliplatin combinations with bevacizumab, two phase III trials 
have demonstrated that an active maintenance therapy (with fluo-
ropyrimidine and bevacizumab) moderately prolongs PFS without 
significantly improving OS [28, 29]. In regard of the results of the 
CAIRO 3 trial, 4.5 months should be regarded as the optimum du-
ration of induction therapy [29].
Later-Line Therapy
Second-line treatment depends on the combination of chemo-
therapy and biological in the first-line setting and should counter-
act an occurred resistance. This includes switching oxaliplatin-
based to irinotecan-based treatment as well as anti-EGFR to anti-
VEGF biological or vice versa. For example, FOLFOX plus bevaci-
zumab yields a significant benefit regarding OS [30]. Of note, the 
continuation of bevacizumab after first progression has shown a 
significant benefit regarding OS [31]. Furthermore, the antiangio-
genic fusion protein aflibercept in combination with FOLFIRI can 
prolong OS after progression upon an oxaliplatin-containing 
chemotherapy irrespective of previous bevacizumab usage [32]. 
With ramucirumab, an anti-VEGFR-2 antibody, the Food and 
Drug Administration has recently approved another beneficial sec-
ond-line option in combination with FOLFIRI [33]. If not previ-
ously given, cetuximab and panitumumab are active as single 
agents in chemorefractory patients with comparable clinical activ-
ity [34]. After failure of the standard treatment options, the multi-
target tyrosine kinase inhibitor regorafenib has shown a significant 
prolongation of OS in the last-line setting [35]. Due to a decision of 
the pharmaceutical company Bayer AG, regorafenib is no longer 
available in Germany as of April 15, 2016.
In later treatment lines, a rechallenge with cetuximab can be 
discussed if patients had achieved a good objective response during 
first-line treatment with this moAb [36]. The current phase III trial 
FIRE-4 investigates this strategy prospectively. A maintenance 
strategy is also incorporated into the innovative study design 
(fig. 2). Another study which also addresses optimal treatment se-
quence is the STRATEGIC-1 trial [37].
Future Perspectives
Patients with BRAF Mutation
Patients with activating BRAF mutation have a dismal progno-
sis even if treated with intensive chemotherapy. Hence, new strate-
gies are urgently needed. First results from targeting the aberrant 
signal transduction are promising, albeit the usage of a single 
BRAF inhibitor has no beneficial effect due to positive feedback ac-
tivation of EGFR [38, 39]. To overcome this, a pilot study exam-
ined the feasibility and efficacy of BRAF inhibitor vemurafenib 
combined with panitumumab [40]. Toxicity was manageable with 
less cutaneous side effects than would be expected with either 
agent. Clinical activity was moderate with an ORR of 17%. This 
could be augmented by further combining BRAF inhibitor dab-
rafenib with panitumumab and MEK inhibitor trametinib in a 
phase I/II study leading to an ORR of 26% with a median PFS of 
4.1 months in heavily pretreated patients [41]. With this combina-
tion, no grade IV toxicity was observed. These promising results 
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Fig. 2. Study design 




Inhibition of the immune checkpoint PD-1 revealed disappoint-
ing results in patients with mCRC [42]. In contrast, patients whose 
tumor showed a mismatch repair deficiency (MMD) derived a 
clinical benefit from PD-1 blockade with pembrolizumab in a 
phase II trial [43]. Median PFS and OS were not reached in pa-
tients suffering from mCRC with MMD but were 2.2 and 5.0 
months, respectively, in the cohort comprising mCRC without 
MMD (hazard ratio 0.1 (p < 0.001) and 0.22 (p = 0.05), respec-
tively). In this study, MMD status was associated with a high so-
matic mutation load, which could serve as predictive biomarker for 
checkpoint inhibition, irrespective of the underlying tumor entity.
Her2/neu
About 5% of mCRC show an overexpression of Her2/neu. A 
phase II trial evaluated the treatment with trastuzumab and lapat-
inib in this subgroup and found a considerable clinical efficacy in 
heavily pretreated patients [44]. The primary end point was met 
with an ORR of 34.7%. Disease control rate was 78%. Treatment 
was well tolerated with no grade 4–5 toxicity. These results deserve 
further clinical assessment to validate Her2/neu as a predictive fac-
tor for the corresponding targeted therapy.
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